Literature DB >> 24315438

Oversight for clinical uses of autologous adult stem cells: lessons from international regulations.

Tamra Lysaght1, Ian Kerridge, Douglas Sipp, Gerard Porter, Benjamin J Capps.   

Abstract

Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.
Copyright © 2013 Elsevier Inc. All rights reserved.

Mesh:

Year:  2013        PMID: 24315438     DOI: 10.1016/j.stem.2013.11.013

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  6 in total

Review 1.  Autologous bone marrow stem cell transplantation for the treatment of ulcerative colitis complicated with herpes zoster: a case report.

Authors:  Hang Xiang; Xiaomei Zhang; Chao Yang; Wenhuan Xu; Xin Ge; Rong Zhang; Ya Qiu; Wanjun Sun; Fan Li; Tianyuan Xiang; Haixu Chen; Zheng Wang; Qiang Zeng
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

2.  Osthole enhances the immunosuppressive effects of bone marrow-derived mesenchymal stem cells by promoting the Fas/FasL system.

Authors:  Yang Yu; Meng Chen; Shiyao Yang; Bingyi Shao; Liang Chen; Lei Dou; Jing Gao; Deqin Yang
Journal:  J Cell Mol Med       Date:  2021-03-21       Impact factor: 5.310

3.  Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.

Authors:  Amy Zarzeczny; Marianne Clark
Journal:  BMC Med Ethics       Date:  2014-10-14       Impact factor: 2.652

Review 4.  The malignant niche: safe spaces for toxic stem cell marketing.

Authors:  Douglas Sipp
Journal:  NPJ Regen Med       Date:  2017-12-19

5.  Challenges in the translation and commercialization of cell therapies.

Authors:  Brittany P Dodson; Aaron D Levine
Journal:  BMC Biotechnol       Date:  2015-08-07       Impact factor: 2.563

6.  Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments.

Authors:  Geoffrey P Lomax; Art Torres; Maria T Millan
Journal:  Stem Cells Transl Med       Date:  2020-02-10       Impact factor: 6.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.